IFNB1 and cancer: Forinstance, PME-2539 (Figure 4C), may warrant additional study in a cancer immunotherapyas it upregulates beneficial antitumor cytokines and chemokines.40,41 This compound can enhance TNF-α up to 36-fold using cGAMPand is shown to enhance IFN-β secretion across all agonistsstudied.